scholarly journals Case report: Symptomatic pericarditis post covid-19 vaccination

2021 ◽  
Author(s):  
Sarah Ashaari ◽  
Hafiz Ahmed Sohaib ◽  
Kenneth Bolger
Keyword(s):  
Case Report ◽  
Disease Control ◽  
Side Effect ◽  
Rapid Development ◽  
Symptomatic Relief ◽  
Side Effect Profile ◽  
First Line ◽  
Post Vaccination ◽  
Case Summary ◽  
Control And Prevention

Abstract Background The Covid-19 pandemic has led to rapid development of Covid-19 vaccine. Centers for Disease Control and Prevention (CDC) has recently reported increase in myopericarditis incidence post Covid-19 vaccination. Post-vaccination myo-pericarditis as side effect has been reported however is infrequent. We described a case of pericarditis post- first dose of Pfizer-BioNTech vaccine. Case Summary A patient presented with typical symptoms of pericarditis and related ECG and echocardiogram changes, 7 days post receiving the first dose of Covid-19 vaccine. No other causes were identified from series of investigations. Patient had good symptomatic relief with non-steroidal anti- inflammatory medication. Conclusion The incidence of pericarditis post-vaccination is rare, with limited reporting in previous literatures. No causal relationship has yet to be established due to small number of cases. The benefits of Covid-19 vaccination currently outweigh the side effect profile and recommended as the first line approach to control the current pandemic.

scholarly journals Kikuchi–Fujimoto Disease Post COVID-19 Vaccination: Case Report and Review of Literature

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1251
Author(s):  
Hui Min Tan ◽  
Susan Swee-Shan Hue ◽  
Aileen Wee ◽  
Kay Choong See
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Literature Review ◽  
Side Effect ◽  
Clinical Course ◽  
Rapid Development ◽  
Asian Population ◽  
Common Side Effect ◽  
Review Of Literature ◽  
Post Vaccination

With the rapid development of various coronavirus disease 2019 (COVID-19) vaccines in a bid to counter and contain the COVID-19 pandemic, unusual and uncommon side effects of COVID-19 vaccination have been increasingly reported in the literature. Ipsilateral lymphadenopathy is a fairly common side effect of vaccination of any kind, with its etiology most commonly related to reactive lymphadenopathy. However, Kikuchi–Fujimoto Disease (KFD) or necrotizing histiocytic lymphadenitis is rarely observed post-vaccination, with only one other case of KFD post COVID-19 vaccination reported to date. We report two more cases of KFD post COVID-19 vaccination in the Asian population, highlighting the clinical course and salient clinical, radiological and histologic findings. In addition, we provide a literature review of the existing cases of lymphadenopathy post COVID-19 vaccination with cytologic and/or histologic correlation.

Citalopram-Associated Alopecia: A Case Report and Brief Literature Review

2019 ◽  
Vol 14 (2) ◽  
pp. 167-170 ◽  
Author(s):  
Joshua Hekmatjah ◽  
Kinza Tareen ◽  
Ruqiya Shama Tareen
Keyword(s):  
Quality Of Life ◽  
Case Report ◽  
Side Effect ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Early Recognition ◽  
Side Effect Profile ◽  
First Line ◽  
Drug Induced ◽  
Bizarre Behavior

Background: Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line treatments for various psychiatric disorders. SSRIs offer an improved side effect profile compared to older treatments, which improves patients’ adherence and quality of life. Case Report:Here we discuss a case of an uncommon, but a distressing side effect of citalopram. A 76-year old woman was referred to the psychiatry clinic for bizarre behavior. The patient was diagnosed with behavioral variant frontotemporal dementia and was started on citalopram 20 mg and aripiprazole 5 mg daily. At 3.5 months the patient complained of diffuse hair thinning on her scalp. Citalopram was considered the offending agent and was discontinued. Within a few months, the patient regained most of her hair. Although drug-induced alopecia is common among other SSRIs, it is relatively rare with citalopram. Results and Conclusion:Early recognition, withdrawal of offending agent, and reassurance to the patient that hair loss is reversible can help alleviate patient distress and avoid relapse.

A CASE OF POSTPARTUM MORTALITY DUE TO COVID-19 INFECTION

2020 ◽  
pp. 1-4
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Case Report ◽  
Disease Control ◽  
Cesarean Delivery ◽  
Morbidly Obese ◽  
New Disease ◽  
Current Case ◽  
Infected Woman ◽  
Control And Prevention

The current case report is presenting a post her third cesarean delivery COVID-19 infected woman who was 35years old, morbidly obese, and asthmatic. As coronavirus disease 2019 (COVID-19) is a new disease, its information is constantly being updated. Earlier reports of COVID 19 claims that pregnancy did not affect the progress of the disease severity. Recently, the Centers for Disease Control and Prevention (CDC) announced that pregnancy is a risk factor for COVID-19 severity. In the current case, her pregnancy may aggravate the criticality of COVID-19 infection in the addition to of her other risk factors (age, asthma, and obesity) up to death.

Pharmacotherapy

2012 ◽  
Author(s):  
Raymond W. Lam
Keyword(s):  
Side Effect ◽  
First Generation ◽  
Side Effect Profile ◽  
Comorbid Conditions ◽  
First Line ◽  
Selection Of

• The newer antidepressants (SSRIs, SNRIs, other receptor agents) are first-line medications due to improved safety and tolerability over first-generation medications (TCAs, MAOIs).• Selection of an antidepressant must take into account efficacy, depression subtype, safety, side effect profile, simplicity of use, comorbid conditions, concurrent medications, and cost....

Esotropia in a Child Treated With a Scopolamine Patch for Drooling

PEDIATRICS ◽  
1996 ◽  
Vol 97 (1) ◽  
pp. 126-127
Author(s):  
William V. Good ◽  
Lucy S. Crain
Keyword(s):  
Case Report ◽  
Side Effect ◽  
Protein C ◽  
Side Effect Profile ◽  
Protein C Deficiency ◽  
Neurodevelopmental Disabilities ◽  
Care Givers ◽  
Substantial Problem ◽  
Spastic Quadriplegia ◽  
Clotting Disorder

Drooling in children who have neurodevelopmental disabilities can pose a substantial problem. Recent studies have indicated that, because of its anticholinergic effect, the use of a scopolamine patch may help eliminate drooling.1,2 The ease of administration of the patch, coupled with its very low side-effect Profile, adds to its desirability. However, we want to alert care givers to a problem we attribute to the scopolamine patch. Esotropia developed in one of our patients when scopolamine transdermal patching was done. The esotropia resolved shortly after cessation of patching. CASE REPORT This 4-year-old boy has spastic quadriplegia, a significant developmental delay, a well-controlled seizure disorder, and microcephaly secondary to a neonatal cerebrovascular hemorrhage associated with a protein C deficiency clotting disorder.

scholarly journals Risperidone-associated enuresis—a case report

2021 ◽  
Vol 28 (1) ◽  
Author(s):  
Ashish Sarangi ◽  
Zachary Mkhantar ◽  
Preston Weaver
Keyword(s):  
Decision Making ◽  
Case Report ◽  
Side Effect ◽  
Negative Symptoms ◽  
Informed Decision Making ◽  
Side Effect Profile ◽  
Case Presentation ◽  
Potential Side Effect ◽  
Metabolic Side Effect ◽  
Positive And Negative Symptoms

Abstract Background Risperidone has been reported to be effective in treating both the positive and negative symptoms of schizophrenia, aggression, and behavioral disorders. While the metabolic side effect profile of this medication has been broadly studied, studies related to this medication’s bladder effects are relatively rare. We present a case of risperidone-induced enuresis in an adult male with schizophrenia that resolved upon discontinuation of the offending medication. Case presentation We describe a case of a 32-year-old man with a primary psychotic disorder who developed debilitating enuresis secondary to taking risperidone. Enuresis resolved upon switching to Seroquel. Conclusion Enuresis secondary to risperidone is not commonly discussed prior to initiation by the treating psychiatrist however can be debilitating. Discussing this potential side effect is critical to informed decision making on the patient’s part.

Safety of sublingual grass pollen immunotherapy after anaphylaxis

2008 ◽  
Vol 123 (6) ◽  
pp. 683-684 ◽  
Author(s):  
J R Nichani ◽  
J de Carpentier
Keyword(s):  
Case Report ◽  
Adverse Events ◽  
Grass Pollen ◽  
Side Effect ◽  
Sublingual Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Side Effect Profile ◽  
Fatal Complication ◽  
Discontinuation Of Treatment ◽  
Safe Treatment Option

AbstractAim:To demonstrate that sublingual immunotherapy is a safe treatment option in patients who have previously suffered anaphylaxis when undergoing subcutaneous grass pollen immunotherapy.Case report:We report two patients who developed a systemic anaphylactic reaction following subcutaneous grass pollen immunotherapy, resulting in discontinuation of treatment. Following treatment of the acute anaphylactic episode, both patients were subsequently safely commenced on sublingual grass pollen immunotherapy.Conclusion:Injection immunotherapy has a relatively low risk of severe adverse events, although anaphylaxis is a potentially fatal complication and usually results in termination of the immunotherapy programme. Sublingual immunotherapy has a safer side effect profile than subcutaneous immunotherapy, with no reported cases of anaphylaxis.

scholarly journals SAT-278 Vaginal Cabergoline: A Simple Solution to a Challenging Problem

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Munder Abuaisha ◽  
Otto Gibbs ◽  
Rachel Bier
Keyword(s):  
Pituitary Adenoma ◽  
Side Effect ◽  
Gamma Knife Radiosurgery ◽  
Sella Turcica ◽  
Serum Prolactin ◽  
Side Effect Profile ◽  
First Line ◽  
Optic Chiasma ◽  
Persistent Symptoms ◽  
Favorable Side Effect Profile

Abstract Introduction: Prolactinomas is a common endocrine disorder that can be associated with significant morbidity. Generally, prolactinomas are more responsive to pharmacologic treatment than any other types of pituitary adenoma. Dopamine agonists (DA), including cabergoline and bromocriptine, are the first line of treatment in all sizes of prolactinomas and they decrease both the secretion and size of these adenomas. However, treatment remains challenging for patients who are intolerance to those medications. Case: We report a 32-year-old Hispanic woman who presented with secondary amenorrhea, she was found to have hyperprolactinemia of 1496 mcg/L. MRI of the brain showed a pituitary adenoma measuring 2.7 cm with sella turcica invasion and mass effect on the optic chiasma. She failed the lowest doses of oral cabergoline and bromocriptine and underwent TSS and gamma knife radiosurgery. Given her persistent symptoms (marked depression, insomnia, fatigue, short-term memory loss, and lack of concentration along with constipation) and elevation of prolactin, she was started on low dose vaginal cabergoline leading to a marked improvement of her symptoms and a steady decrease in serum prolactin. Discussion: Despite the availability of DA as a first-line treatment of Prolactinoma, treatment remains challenging, given the commonly reported side effects for all DA. Cabergoline is oftentimes the treatment of choice due to efficacy and favorable side-effect profile. However, intolerance to those medications can lead to discontinuation of therapy and increase morbidity. Other strategies, including transsphenoidal surgery (TSS) or radiation therapy, have been considered for the minority of patients whose adenomas are resistant to DA or who cannot tolerate these drugs. Interestingly, tolerance to DA can be improved by administering the drug intravaginally, which can have similar efficacy to the oral route and a more favorable side-effect profile. However, only a few studies assessed the effectiveness and tolerance of vaginal DAs in hyperprolactinemic patients intolerant to oral medications, little evidence supports the use of intravaginal DA to improve drug tolerance, and further studies are necessary to determine the safety and efficacy of vaginal cabergoline.

scholarly journals Cutaneous leishmaniasis in a 65-year-old North Texas male, treated with cryotherapy: A case report

2020 ◽  
Vol 8 ◽  
pp. 2050313X2090459
Author(s):  
Daniel A Nguyen ◽  
Jean Elizze M Charles ◽  
J Trace Worrell ◽  
Dustin V Wilkes
Keyword(s):  
Infectious Disease ◽  
Case Report ◽  
Disease Control ◽  
Granulomatous Inflammation ◽  
North Texas ◽  
Dermatology Clinic ◽  
Control And Prevention ◽  
Infectious Disease Specialists ◽  
Central Ulceration

We report a case of a 65-year-old male seen in a North Texas dermatology clinic with three erythematous nodules possessing central ulceration and scaling on the left lateral shoulder, present for months. Head, ears, lips, oral mucosa, and other body surfaces did not reveal similar lesions, and review of systems was negative. Shave biopsy was performed and histopathological findings demonstrated granulomatous inflammation in the dermis and parasitized histiocytes containing peripherally located amastigotes. Leishmaniasis was diagnosed and patient was educated on the disease while communication with the Centers for Disease Control and Prevention was initiated. The patient declined systemic medications from infectious disease specialists and, 3 weeks later, returned for follow-up treatment with cryotherapy.

New onset multimodal hallucinations associated with mirtazapine: a case report

2010 ◽  
Vol 22 (5) ◽  
pp. 837-839 ◽  
Author(s):  
Kalpana P. Padala ◽  
Prasad R. Padala ◽  
Timothy Malloy ◽  
William J. Burke
Keyword(s):  
Weight Loss ◽  
Case Report ◽  
Side Effect ◽  
The Elderly ◽  
Side Effect Profile ◽  
Visual Hallucinations ◽  
Care Needs ◽  
Treatment Of Depression ◽  
Safe Side ◽  
New Onset

ABSTRACTMirtazapine, a commonly used antidepressant, has a relatively safe side effect profile and is commonly used in the elderly for treatment of depression. It has been proposed as being particularly suitable for patients with depression associated with insomnia and weight loss. Although mental status changes and perceptual abnormalities secondary to its use are rare, special care needs to be taken, especially while starting treatment or while increasing the dose. We report three cases of auditory, musical and visual hallucinations associated with the use of mirtazapine.

Sign in / Sign up

Export Citation Format

Share Document